| Updated on March 13, 2018 Published on April 12, 2017

Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg. This is to inform you that the US FDA has issued an Establishment Inspection Report (EIR) for the Companys Active Pharmaceutical Ingredient (API) manufacturing facilities located at Raichur, Karnataka, India which was inspected between 12th and 16th December 2016. The inspection has now been closed by the US FDA. The Company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The US FDA has reviewed the CAPA and has found them acceptable.

Pdf Link: Updates

Source : BSE - www.bseindia.com

Published on April 12, 2017
This article is closed for comments.
Please Email the Editor